<DOC>
	<DOCNO>NCT01261169</DOCNO>
	<brief_summary>This study design explore use Myfortic® patient steroid-refractory uveitis . The aim study show therapeutic effect Myfortic® managing uveitis patient .</brief_summary>
	<brief_title>Mycophenolate Sodium ( Myfortic® ) Treatment Corticosteroid-refractory Autoimmune Uveitis : Pilot Study</brief_title>
	<detailed_description>This study single arm prospective evaluation patient uveitis treat Myfortic® dose 360 mg bid six month . From day 0 , Myfortic combine 1 mg/kg prednisone . Prednisone taper week 1 base clinical finding ophthalmologist . There stratification patient . After screen , patient treat Myfortic® 6 month . Patients see month 1 , 3 , 6 . Thereafter patient follow month 12 . Efficacy safety assessment perform visit .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Men woman ≥ 18 year age corticosteroidrefractory uveitis due one inflammatory condition list : 1 . Ocular sarcoidosis : granulomatous uveitis posterior inflammation patient sarcoidosis establish mean biopsy , cytology , positive scan . 2 . Intermediate uveitis : patient clinical feature define IUSG23 . However , important patient evidence systemic infection Lyme Borreliosis history neurological symptom likely associate multiple sclerosis . All patient intermediate uveitis negative MRI gadolinium contrast , prior enrol . 3 . Behçet 's syndrome : international classification criterion International Society Behçet 's Disease ( ISBD ) use define patient . 4 . Idiopathic Retinal Vasculitis systemic infectious cause eliminate . In particular patient evidence Wegener 's granulomatosis , SLE , PAN , polymyositis , dermatomyositis systemic vasculitic disorder . Patients must also lack evidence systemic infection , adequately screen . For purpose study , Eale 's disease exclude idiopathic retinal vasculitis group . However , nonocclusive occlusive type retinal vasculitis include study . 5 . VogtKoyanagiHarada disease ( VKH ) define accord international Workgroup definition VKH . 6 . Sympathetic ophthalmia : granulomatous uveitis involve choroid retina , characterize multiple whiteyellow lesion often periphery , coalesce particularly circumpapillary region . It associate trauma multiple prior surgery . 7 . Idiopathic panuveitis : noninfectious panuveititides related disease mention . 8 . Corticosteroidrefractory uveitis patient define patient receive steroid treatment low dosage steroid le 10mg per day 3 month due clinical condition . 2 . Disease 5 year less duration , significant flare past 24 month require intensification antiinflammatory therapy ( predsinolone ) . A significant flare define drop 2 line vision ETDRS chart equivalent , increase vitreous flare 2 grade . 3 . Visual acuity 0.1 good least one eye . 4 . Men woman childbearing potential must use adequate birth control measure ( e.g. , abstinence , oral contraceptive , intrauterine device , barrier method spermicidal cream , surgical sterilization ) duration study continue precaution 6 week receive last administration . 5 . The screen laboratory test result must meet following criterion : 1 . Hemoglobin ≥ 10.5 g/dL 2 . WBC ≥ 3.0 x 103/μL 3 . Neutrophils ≥ 1.5 x 103/μL 4 . Platelets ≥ 1 x 103/μL 5 . SGOT ( AST ) alkaline phosphatase level must within 3 time upper limit normal range laboratory conduct test ( 3xULN ) . 6 . Creatinine clearance &gt; 25 ml/min 6 . Must normal chest radiograph within 3 month prior first therapy evidence malignancy , infection TB . 7 . Patient must able adhere study visit schedule protocol requirement . 8 . The patient must capable give informed consent consent must obtain prior screen procedure . 1 . Inability visualize fundus due corneal lenticular opacity . 2 . Patients require ocular surgery within initial 3 month treatment , surgery prior 3 month . 3 . Women pregnant , nursing , plan pregnancy within 6 month screen ( i.e. , approximately 6 week follow last treatment ) . 4 . Use investigational drug within 1 month prior screen within 5 halflives investigational agent , whichever longer . 5 . Recent history systemic immunosuppressive therapy , steroid ocular disease within 2 month . 6 . Creatinine clearance &lt; 25ml/min serum creatinine level high 1.5 mg/dl 7 . Patients know hypersensitivity prednisone , Myfortic® drug similar chemical structure . 8 . Patients clinically significant infection . 9 . Documented HIV infection . 10 . Patients active TB evidence latent TB . 11 . Patients positive Lues serology significant Lues infection . 12 . Patients opportunistic infection , include limited evidence active cytomegalovirus , active Pneumocystis carinii , Aspergillosis , Histoplasmosis atypical mycobacterium infection , etc , within previous 6 month . 13 . Current sign symptom severe , progressive uncontrolled renal , hepatic , hematologic , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral disease . 14 . Presence transplant organ ( exception corneal transplant 3 month prior screen ) . 15 . Malignancy within past 5 year ( except treat squamous basal cell carcinoma skin without evidence recurrence ) . 16 . History lymphoproliferative disease include lymphoma , sign symptom suggestive possible lymphoproliferative disease , lymphadenopathy unusual size location ( nodes posterior triangle neck , infraclavicular , epitrochlear , periaortic area ) , splenomegaly . 17 . Known recent substance abuse ( drug alcohol ) . 18 . Poor tolerability venipuncture lack adequate venous access require blood sample study period . 19 . Recent live vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Mycophenolate sodium ( Myfortic® )</keyword>
	<keyword>Corticosteroid-refractory autoimmune Uveitis</keyword>
</DOC>